WO2024252366 - GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS
National phase entry:
Publication Number
WO/2024/252366
Publication Date
12.12.2024
International Application No.
PCT/IB2024/055618
International Filing Date
07.06.2024
Title **
[English]
GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS
[French]
AGONISTES DU RÉCEPTEUR DOUBLE GLP-1/GIP, DOUBLE GLP-1/GCG ET TRIPLE GLP-1/GIP/GCG
Applicants **
SUN PHARMACEUTICAL INDUSTRIES LIMITED
Inventors
THENNATI, Rajamannar
BURADE, Vinod Sampatrao
NATARAJAN, Muthukumaran
JOSHI, Dhiren Rameshchandra
GANDHI, Manish Harendraprasad
JIVANI, Chandulal Thakarshiibhai
TIWARI, Abhishek
SONI, Krunal Harishbhai
MARU, Alpeshbhai Balabhai
DIXIT, Pankaj Vinodrao
PATELIYA, Bharatbhai Balabhai
NAGARAJA, Ravishankara Madavati
Priority Data
202321039646
09.06.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3037 | |
| EPO | Filing, Examination, Granting | 19977 | |
| Japan | Filing, Examination, Granting | 2887 | |
| South Korea | Filing, Examination, Granting | 3528 | |
| USA | Filing, Examination, Granting | 16940 |
Total:
46,369
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to GLP-1/GIP/GCG triple receptor agonists and use thereof in the treatment or prevention of Type 2 diabetes mellitus (T2DM), hyperlipidemia/dyslipidemia, metabolic syndromes, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), neurodegenerative disorders, fibrosis, cardiovascular risks, and/or obesity.[French]
La présente invention concerne des agonistes du récepteur triple GLP-1/GIP/GCG et leur utilisation dans le traitement ou la prévention du diabète sucré de type 2 (T2DM), de l'hyperlipidémie/dyslipidémie, de syndromes métaboliques, de la stéatose hépatique associée à un dysfonctionnement métabolique (MASLD), de la stéatohépatite associée à un dysfonctionnement métabolique (MASH), de troubles neurodégénératifs, de la fibrose, de risques cardiovasculaires et/ou de l'obésité.